We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sequenom's Technology Used for Epigenomic Studies and Genotyping

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Sequenom's Technology Used for Epigenomic Studies and Genotyping"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Sequenom, Inc. has announced that The University of Texas M. D. Anderson's Kleberg Center for Molecular Markers has purchased Sequenom's proprietary MassARRAY genetic analysis system and iPLEX assay for the Center's molecular marker research and individualized cancer care initiatives.

"We will use Sequenom's technology for genotyping and epigenomic studies in support of our efforts to identify individuals at high risk for developing specific types of cancer, develop screening approaches for early diagnosis of cancer, and tailor therapy to the genetic make-up of each patient," said Gordon Mills, M.D., Ph.D., chair of the Department of Molecular Therapeutics and co-director of the Kleberg Center. 

"Sequenom's MassARRAY platform is particularly attractive for our needs because it enables us to do many types of studies in a cost-effective manner, on a single platform, e.g., genotyping, quantitative gene expression, and quantitative methylation marker analysis."
"We are proud that Sequenom's technology was chosen by the Kleberg Center for their cancer pharmacogenetic needs and we hope to expand our relationship with this prominent institution in the future," stated Harry Stylli, MBA, Ph.D., President and Chief Executive Officer of Sequenom, Inc. 

"The MassARRAY system's multi-application versatility and quantitative capabilities differentiate it from other technologies and make it especially well-suited for the demands of cancer research."

"Our iPLEX assay also answers the needs of leading research organizations such as the Kleberg Center by reducing reagent costs per genotype and offering efficient assay design."

"We are pleased to see validation of our efforts to provide the most advanced cancer research centers with the most enabling tools."